- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03333135
Ultramarathons and Impact of Phased Electromagnetic Field Therapy (PEMF)
April 1, 2022 updated by: Bruce Johnson, Mayo Clinic
The Pulmonary Consequences of Participating in the UTMB and Hong Kong 100 Ultramarathons and Impact of Phased Electromagnetic Field Therapy (PEMF)
This research is being done to better understand the pulmonary consequences of completing an ultra marathon at altitude and a sea level city.
Study Overview
Status
Completed
Conditions
Detailed Description
Subjects will be asked to undertake three (3) sets of assessments at prescribed time intervals: Baseline (at 72-24h prior to each event), immediately post (within 2h of race completion) and during recovery (within 24-48h of race completion).
Each assessment will consist of 1)lung function tests; 2) a saliva and blood sample; 3) a lung and cardiac ultrasound.
Subjects will be recruited from a range of age groups and fitness levels, before being divided into a sham or therapy group.
Groups will use Pulsed Electromagnetic Field (PEMF) therapy or related sham before the event and during recovery.
Study Type
Interventional
Enrollment (Actual)
72
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic in Rochester
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
Healthy endurance trained individuals participating in the Ultra Trail du Mont Blanc (UTMB) and/or Hong Kong 100 ultramarathons
Exclusion Criteria:
> 65 years age
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: HK100 Pulsed Electromagnetic Field
20 athletes (ideally a mix of elite and amateur level athletes and veteran (40-65y) and young (20-39y).
Athletes will be recruited at the 2018 and 2019 Hong Kong 100 races.
In addition, these athletes will use the pulsed electromagnetic field (PEMF) for the two weeks prior to the race.
|
PEMF Therapy based on Biological Electromagnetic (BEM) microbial wave technology provides micro-magnetic emissions to the center of the palm (Laogong acupoint).
While participating in the study, the subjects will undertake 2 sessions of therapy every day (1 session in the morning and evening).
Each session will last for 16-min (8-min for left and 8-min for right hand).
Other Names:
|
|
SHAM_COMPARATOR: HK100 Pulsed Electromagnetic Field Sham
20 athletes (ideally a mix of elite and amateur level athletes and veteran (40-65y) and young (20-39y).
Athletes will be recruited at the 2018 and 2019 Hong Kong 100 races.
In addition, these athletes will use a PEMF device that doesn't produce electromagnetic fields (sham) for the two weeks prior to the race.
|
PEMF therapy will be administered however it will not produce micro-magnetic emissions.
The therapy will be used on the center of the palm (Laogong acupoint) of each hand.
While participating in the study, the subjects will undertake 2 sessions of therapy every day (1 session in the morning and evening).
Each session will last for 16-min (8-min for left and 8-min for right hand).
Other Names:
|
|
EXPERIMENTAL: UTMB Pulsed Electromagnetic Field
20 athletes (ideally a mix of elite and amateur level athletes and veteran (40-65y) and young (20-39y).
Athletes will be recruited at the 2018 and 2019 Ultra Trail du Mont Blanc (UTMB) races.
In addition, these athletes will use the pulsed electromagnetic field (PEMF) for the two weeks prior to the race.
|
PEMF Therapy based on Biological Electromagnetic (BEM) microbial wave technology provides micro-magnetic emissions to the center of the palm (Laogong acupoint).
While participating in the study, the subjects will undertake 2 sessions of therapy every day (1 session in the morning and evening).
Each session will last for 16-min (8-min for left and 8-min for right hand).
Other Names:
|
|
SHAM_COMPARATOR: UTMB Pulsed Electromagnetic Field Sham
20 athletes (ideally a mix of elite and amateur level athletes and veteran (40-65y) and young (20-39y).
Athletes will be recruited at the 2018 and 2019 Ultra Trail du Mont Blanc (UTMB) races.
In addition, these athletes will use a PEMF device that doesn't produce electromagnetic fields (sham) for the two weeks prior to the race.
|
PEMF therapy will be administered however it will not produce micro-magnetic emissions.
The therapy will be used on the center of the palm (Laogong acupoint) of each hand.
While participating in the study, the subjects will undertake 2 sessions of therapy every day (1 session in the morning and evening).
Each session will last for 16-min (8-min for left and 8-min for right hand).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in right ventricle end diastolic area (EDA)
Time Frame: baseline, within 2 hours of race completion, 24-48 hours post race
|
Cardiac ultrasound (Philips CX50) will be performed to determine left and right ventricular morphology and function.
Ultrasound will be performed in accordance with the recommendations of the American Society of Echocardiography guidelines (ASE).
Imaging of the ventricles and the diameter during relaxation (diastole) will be captured and evaluated.
Normal value for right ventricle EDA indexed to body surface area ranges between 5-12.6 cm^2/m^2 for males and 4.5-11.5 cm^2/m^2 for females .
|
baseline, within 2 hours of race completion, 24-48 hours post race
|
|
Change in tricuspid annular plane systolic excursion (TAPSE)
Time Frame: baseline, within 2 hours of race completion, 24-48 hours post race
|
Another ultrasound metric that will be evaluated is tricuspid annular plane systolic excursion (TAPSE) which is used a parameter of global RV function which describes apex-to-base shortening.
Normal value for TAPSE is above 16 mm.
|
baseline, within 2 hours of race completion, 24-48 hours post race
|
|
Change in ratio between early mitral inflow velocity and mitral annular early diastolic velocity (E/e')
Time Frame: baseline, within 2 hours of race completion, 24-48 hours post race
|
Another ultrasound metric that will be evaluated is early mitral inflow velocity and mitral annular early diastolic velocity (E/e') which is used to evaluate the diastolic or relaxation function of the left ventricle.
Normal value for E/e' is <6.
|
baseline, within 2 hours of race completion, 24-48 hours post race
|
|
Change in the ratio of peak velocity flow in early diastole (the E wave) to peak velocity flow in late diastole caused by atrial contraction (the A wave)
Time Frame: baseline, within 2 hours of race completion, 24-48 hours post race
|
Another ultrasound metric that will be evaluated is he ratio of peak velocity flow in early diastole (the E wave) to peak velocity flow in late diastole caused by atrial contraction (the A wave) (E/A) which is used to evaluate the diastolic filling of the left ventricle.
Normal value for E/A is between 0.8 and 2.
|
baseline, within 2 hours of race completion, 24-48 hours post race
|
|
Change in lung fluid assessed through ultrasound incidence of comet tails
Time Frame: baseline, within 2 hours of race completion, 24-48 hours post race
|
Ultrasound will be used to image 28 "windows" covering the 2nd through the 5th intercostal/rib space on the right and left sides of the chest.
The number of comet tails observed over these 28 locations will be documented and the change in this number over the course of the study will be evaluated.
|
baseline, within 2 hours of race completion, 24-48 hours post race
|
|
Change in lung fluid assessed through diffusion capacity of the lungs for carbon monoxide and nitric oxide
Time Frame: baseline, within 2 hours of race completion, 24-48 hours post race
|
Subjects will take a maximal breath of a test gas mixture, hold that inhalation for 4 seconds and then exhale and the exhaled gas will be analyze to determine the change in gas concentrations between what was inhaled and exhaled.
Comparison will be made between the change over time in this ability of gas to move from the lungs to the blood stream.
|
baseline, within 2 hours of race completion, 24-48 hours post race
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in exhaled nitric oxide
Time Frame: baseline, within 2 hours of race completion, 24-48 hours post race
|
The amount of nitric oxide in ones exhaled air will be measured by a handheld device.
Levels under 25 parts per billion are normal, more than 35 parts per billion would be a sign of airway inflammation.
|
baseline, within 2 hours of race completion, 24-48 hours post race
|
|
Change in hemoglobin
Time Frame: baseline, within 2 hours of race completion, 24-48 hours post race
|
A blood sample will be taken and analyzed to determine the amount of red blood cells and and hemoglobin in the blood.
For males normal range for hemoglobin is 13.5-17.5
grams per deciliter and for females normal range for hemoglobin is 12.0-15.5
grams per deciliter.
Low values means anemia is present and higher levels is a normal response to altitude.
|
baseline, within 2 hours of race completion, 24-48 hours post race
|
|
Change in hematocrit
Time Frame: baseline, within 2 hours of race completion, 24-48 hours post race
|
A blood sample will be taken and analyzed to determine the amount of red blood cells and and hemoglobin in the blood.
For males normal range for hematocrit is 38.8-50% and for females normal range for hematocrit is 34.9-44.5%
Low values means anemia is present and higher levels is a normal response to altitude.
|
baseline, within 2 hours of race completion, 24-48 hours post race
|
|
Change in cardiac troponin I
Time Frame: baseline, within 2 hours of race completion, 24-48 hours post race
|
To determine if signs of cardiac damage, as its presence in the blood is a potential sign of damage to the heart muscle
|
baseline, within 2 hours of race completion, 24-48 hours post race
|
|
Change in B-type natriuretic peptide
Time Frame: baseline, within 2 hours of race completion, 24-48 hours post race
|
To determine if signs of cardiac damage, as its presence in the blood is a potential sign of damage to the heart muscle
|
baseline, within 2 hours of race completion, 24-48 hours post race
|
|
Change in cortisol
Time Frame: baseline, within 2 hours of race completion, 24-48 hours post race
|
Saliva levels of cortisol will be measured as a metric of stress.
Cortisol levels increase when you body is under stress.
|
baseline, within 2 hours of race completion, 24-48 hours post race
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
December 12, 2016
Primary Completion (ACTUAL)
June 15, 2021
Study Completion (ACTUAL)
June 15, 2021
Study Registration Dates
First Submitted
October 27, 2017
First Submitted That Met QC Criteria
November 2, 2017
First Posted (ACTUAL)
November 6, 2017
Study Record Updates
Last Update Posted (ACTUAL)
April 11, 2022
Last Update Submitted That Met QC Criteria
April 1, 2022
Last Verified
April 1, 2022
More Information
Terms related to this study
Other Study ID Numbers
- 17-003843
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.